Brokerages Set Lantheus Holdings, Inc. (NASDAQ:LNTH) Price Target at $131.86

Lantheus Holdings, Inc. (NASDAQ:LNTH) has been assigned an average rating of “Buy” from the seven research firms that are presently covering the stock, Marketbeat.com reports. Seven research analysts have rated the stock with a buy recommendation. The average 1 year price target among analysts that have issued a report on the stock in the last year is $131.86.

A number of research analysts have issued reports on LNTH shares. Truist Financial reaffirmed a “buy” rating and issued a $120.00 target price (down from $135.00) on shares of Lantheus in a report on Friday, November 8th. The Goldman Sachs Group initiated coverage on Lantheus in a report on Wednesday, December 18th. They set a “buy” rating and a $143.00 price objective for the company. StockNews.com lowered Lantheus from a “buy” rating to a “hold” rating in a report on Thursday, November 21st. JMP Securities cut their price target on Lantheus from $125.00 to $112.00 and set a “market outperform” rating for the company in a research note on Thursday, November 7th. Finally, Redburn Atlantic began coverage on shares of Lantheus in a research note on Tuesday, September 3rd. They issued a “buy” rating and a $175.00 price objective on the stock.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in LNTH. Signaturefd LLC lifted its stake in shares of Lantheus by 40.5% during the 3rd quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider’s stock worth $35,000 after purchasing an additional 92 shares during the period. UMB Bank n.a. increased its stake in Lantheus by 42.1% in the third quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider’s stock valued at $47,000 after purchasing an additional 126 shares during the last quarter. GAMMA Investing LLC lifted its position in Lantheus by 45.5% during the third quarter. GAMMA Investing LLC now owns 467 shares of the medical equipment provider’s stock worth $51,000 after buying an additional 146 shares during the period. Wilmington Savings Fund Society FSB acquired a new stake in Lantheus in the 3rd quarter worth about $25,000. Finally, Nisa Investment Advisors LLC grew its holdings in Lantheus by 4.5% in the 2nd quarter. Nisa Investment Advisors LLC now owns 6,643 shares of the medical equipment provider’s stock valued at $533,000 after buying an additional 287 shares during the period. Institutional investors and hedge funds own 99.06% of the company’s stock.

Lantheus Stock Down 2.9 %

NASDAQ:LNTH opened at $89.29 on Friday. Lantheus has a fifty-two week low of $50.20 and a fifty-two week high of $126.89. The firm’s fifty day simple moving average is $96.17 and its 200-day simple moving average is $98.45. The stock has a market cap of $6.21 billion, a PE ratio of 14.86 and a beta of 0.45.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.